Table 2.
Demographic and Clinical Characteristics of the 11 Post-HCT Controls
| Post-HCT Controls (n = 11) | Subject ID | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | Summary1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographics2 | Age, y | 66 | 25 | 71 | 52 | 65 | 59 | 59 | 65 | 62 | 63 | 57 | 62 (57–65) |
| Race | C | C | C | C | C | C | C | C | AAn | C | AAn | 82% C 18% AAn |
|
| Sex | M | F | M | F | M | M | M | M | M | F | M | 73% M | |
| BMI | 26 | 40 | 26 | 43 | 31 | 24 | 27 | 26 | 36 | 45 | 35 | 31 (26–40) | |
| Disease characteristics3 | Disease histology | MF | AA | AML | MDS | NHL | AML | CLL | MDS | AML | AML | ALL | 36% AML 18% MDS 9% ALL 9% MF 9% AA 9% NHL 9% CLL |
| Transplant characteristics4 | Transplant source | PB | BM | PB | CB | PB | PB | PB | PB | - | PB | PB | 8/10 PB 1/10 BM 1/10 CB |
| MyotonPRO session | Days from HCT5 | 329 | 1,785 | 1,301 | 3,276 | 910 | 411 | 2,507 | 4,046 | 857 | 335 | 148 | 910 (335–2,507) |
Abbreviation: AA, aplastic anemia; AAn, African American; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; BMI, body mass index; C, Caucasian; CB, cord blood; CLL, chronic lymphoblastic leukemia; F, female; HCT, hematopoietic cell transplantation; ID, identification; M, male; MDS, myelodysplastic disorder; MF, primary myelofibrosis; NHL, non–Hodgkin’s lymphoma; PB, peripheral blood.
Values are shown as median (interquartile range) for continuous variables and n (%) for categorical variables.
Demographics: C, AAn, M, and F.
Disease characteristics: AML, ALL, CLL, MDS, MF, AA, and NHL.
Transplant characteristics: PB, BM, and CB.
Days from HCT: days between HCT and MyotonPRO measurement session.